COMMUNIQUÉS West-GlobeNewswire
-
MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN‑166 (ibudilast) in ALS patients
15/07/2026 -
NOMAD Power Solutions Strengthens Subsidiary Executive Leadership
15/07/2026 -
Milestone Scientific Launches First Phase of AI Strategy with Pilot Debut of Milo, an AI-enabled Digital Engagement Platform, at ASPN 2026
15/07/2026 -
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
15/07/2026 -
Cannara Reports Record Q3 Revenues and Continued Profitability Accompanied By Expanding National Distribution and Accelerated Capacity Expansion
15/07/2026 -
Smith+Nephew introduces groundbreaking LYNX™ COBLATION™ Laryngeal Wand for ENT surgeons
15/07/2026 -
Cardiff Oncology Announces $10 Million Registered Direct Offering
15/07/2026 -
iTonic Holdings Ltd Issues an Update on its Effort to Develop AI-Powered Cloud Healthcare Platform Designed to Support Nuclear Medicine Treatment Planning and with Potential Future Expansion into Digital Care Delivery
15/07/2026 -
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
15/07/2026 -
Slate Medicines Strengthens Board of Directors with Appointment of Mark W. Hahn
15/07/2026 -
Lark Health Partners with Samsung to Bring AI-Powered Health Coach to U.S. Seniors
15/07/2026 -
Cynet Releases v4.33 Unveiling a New Cross-Site Dashboard and Enhanced SIEM Capabilities
15/07/2026 -
Mixie Technologies, Inc. (OTC: MIXE) Completes Corporate Rebranding and Trading Symbol Change
15/07/2026 -
Cannara annonce un chiffre d’affaires record au troisième trimestre et une rentabilité soutenue, parallèlement à l’extension de sa distribution nationale et à l’accélération de l’augmentation de ses capacités
15/07/2026 -
NewcelX Granted Patent in Brazil for NCEL-101 in Type 1 Diabetes, Expanding Global IP Portfolio
15/07/2026 -
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
15/07/2026 -
NDT Pharmaceuticals, Inc.’s Wholly Owned Subsidiary Good Salt Life, Inc. Reports Strong Online Retail Growth in First Half of 2026
15/07/2026 -
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2026
15/07/2026 -
Fractyl Health Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation
15/07/2026
Pages